West Pharmaceutical Services, Inc.
NYSE:WSTMedical - Instruments & Supplies
+$5.04 today
- Market cap
- $28.14B
- Beta
- 1.18
- P/E (TTM)
- 43.6
- EPS (TTM)
- $7.54
- Dividend yield
- 0.26%
Volume 0.59M
Average 0.85M
WST Other Non-Cash Items
Other non-cash adjustments that reconcile net income to operating cash flow.
West Pharmaceutical Services, Inc.NYSE: WST
Other Non-Cash Items · Q2 FY2026 · quarter ended Jun 2026
Other non-cash items growth accelerates
Q2 FY2026 other non-cash items of $190M (cash outflow) rose 5488.2% year over year, ahead of the +1129.7% change in trailing-twelve-month other non-cash items.
Context
- Other non-cash items amounted to 0.0% of revenue in FY2025, down 0.6 pp from a year earlier.
- Other non-cash items increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +5488.2% holds above the trailing-twelve-month pace of +1129.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Non-Cash Items history
USD · from the cash flow
- Latest · FY2025
- (200K) USD
- Year-over-year change
- +98.8%
| Period | Period end | Other Non-Cash Items | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (200K) | +98.8% |
| FY2024 | 2024-12-31 | (16.3M) | -401.9% |
| FY2023 | 2023-12-31 | 5.4M | -85.0% |
| FY2022 | 2022-12-31 | 36.1M | +4111.1% |
| FY2021 | 2021-12-31 | (900K) | — |
Other Non-Cash Items vs competitors
How WST compares with its peers on the latest reported figures
- Peers report in different currencies, so other non-cash items is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1129.7% is the highest of 5, against a peer median of +132.5%.
- Other non-cash items amounts to 5.5% of revenue for WST, versus a peer median of 2.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $182M USD | +1129.7% | — | 5.5% | |
| LTM Jun 2026 | $67.87M USD | +637.5% | -34.3% | 3.1% | |
| LTM Jun 2026 | €16.97M EUR | +96.0% | — | 1.4% | |
| LTM Jun 2026 | $16.75M USD | +109.0% | +7.8% | 0.4% | |
| LTM Mar 2026 | $5.17M USD | +155.9% | -62.3% | 5.2% | |
| Peer median (excluding WST) | — | +132.5% | -34.3% | 2.3% | |
Competitors are the stored peer set for WST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 661.8M | 585.9M | 593.4M | 492.7M | 493.7M |
| Depreciation & Amortization | 122.3M | 120.6M | 137.3M | 155.4M | 171.4M |
| Deferred Income Tax | (42.9M) | (30.8M) | 37.5M | 0 | (13.7M) |
| Stock-Based Compensation | 37.5M | 23.7M | 23.3M | 18.7M | 23.8M |
| Change in Working Capital | (193.8M) | (15M) | (20.4M) | 2.9M | 79.8M |
| Accounts Receivables | (123.5M) | (35.6M) | 4M | (58.8M) | 6.9M |
| Inventory | (86.5M) | (49.8M) | (13.5M) | 42M | (62.8M) |
| Accounts Payables | 16.8M | (2.8M) | 4.4M | 2.9M | 17.9M |
| Other Working Capital | (600K) | 73.2M | (15.3M) | 16.8M | 117.8M |
| Other Non-Cash Items | (900K) | 36.1M | 5.4M | (16.3M) | (200K) |
| Operating Cash Flow | 584M | 724M | 776.5M | 653.4M | 754.8M |
| Capital Expenditures | (253.4M) | (284.6M) | (362M) | (377M) | (285.9M) |
| Acquisitions (Net) | (2.2M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 2.5M | (3.6M) | (6.7M) | (1.7M) | 0 |
| Investing Cash Flow | (253.1M) | (288.2M) | (368.7M) | (378.7M) | (285.9M) |
| Debt Repayment | (2.2M) | (44.3M) | (2.3M) | (27.6M) | (1.1M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 18.2M |
| Common Stock Repurchased | (151.9M) | (222.2M) | (451.2M) | (566.6M) | (134M) |
| Dividends Paid | (51.1M) | (54.1M) | (57M) | (59.1M) | (61.2M) |
| Other Financing Activities | 37.1M | 27M | 50.9M | 30.7M | (7M) |
| Financing Cash Flow | (168.1M) | (293.6M) | (459.6M) | (622.6M) | (185.1M) |
| Effect of Forex Changes | (15.7M) | (10.5M) | 11.4M | (21.4M) | 22.9M |
| Net Change in Cash | 147.1M | 131.7M | (40.4M) | (369.3M) | 306.7M |
| Free Cash Flow | 330.6M | 439.4M | 414.5M | 276.4M | 468.9M |
West Pharmaceutical Services, Inc.
NYSE:WST
Intrinsic Alpha fair value
Locked
Current Price
$404.02
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.